Journal of International Psychiatry

Abstract Objective: To analyze the effects of fluvoxamine maleate on neurological function, negative mood and monoamine neurotransmitter levels in patients with post-ischemic stroke depression. Methods: A total of 101 patients with depression after ischemic stroke in our department from April 2020 to February 2022 were selected as the research objects and grouped by extraction method. The control group (50 cases) received routine treatment, while the observation group (51 cases) received fluvoxamine maleate. The neurological function, negative emotions, monoamine neurotransmitter levels and adverse reactions were compared between the two groups. Results: The National Institutes of Health Stroke Scale (NIHSS) score and advanced central injury severity (MESSS) were compared between the two groups (P > 0.05). The scores of Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) in the observation group were lower than those in the control group (P < 0.05). The levels of dopamine (DA), 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the observation group were higher than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: Fluvoxamine maleate combined with conventional treatment can effectively improve the neurological function of patients with post-ischemic stroke depression, reduce negative emotions, regulate the level of monoamine neurotransmitters, and has high safety.

Key words: fluvoxamine maleate; Stroke; Depression; Neurological function; Negative emotions; Monoamine neurotransmitter